High dose of Nexium® with aspirin reduces risk of developing esophageal cancer

A Phase III randomized trial has demonstrated that taking a high dose of the acid-reducing medicine esomeprazole (Nexium®) with low dose aspirin for a minimum of 7 years can reduce the risk of developing esophageal cancer, a pre-cancerous lesion termed high-grade dysplasia or delay death from any cause in people with Barrett’s esophagus. This rare condition increases the risk of esophageal disease by 50-fold.